Ebola Study

Age range: 18-45 years of age

Study criteria: Healthy adults who have not been vaccinated or exposed to Ebola or who have not received a smallpox based vaccine.

Contact email: ecc.vaccine@emory.edu

Contact Phone number: 404-727-4044

Study Description

The purpose of this study is to understand the safety of vaccines that were made to protect against infection to a number of filoviruses including Ebola virus and Marburg virus, and how our body responds to these vaccines.  Our understanding of immune responses to these vaccines has mainly been through animal studies. If these vaccines are safe and work, they could become available for preventing Ebola. This study will evaluate the safety and the immune responses to 2 filovirus vaccines, MVA-BN®-Filo and Ad26.ZEBOV, given singly or in combination.

Who Can Participate?

Healthy adults 18 to 45 years of age

What is involved?

The study involves 15-23 clinic visits at Emory Children’s Center, which will range from 1-2 hours each. Subjects will receive two to three doses of the study vaccine, one on their first clinic visit and the next dose within 28 days. Certain subjects will receive a vaccine 12 months after their initial clinic visit.

This study is free. To say thank you, families will be compensated for their time and participation.